The Role of Tumor Mutational Burden in Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.
Richard Parker, MD, provides an overview of this condition, which is common on patients with carcinoid syndrome.
Emily A. Knight, RN of the Mayo Clinic in Scottsdale, AZ, describes issues faced in managing and navigating patients with polycythemia Supported through funding from Incyte